- Home
- GLXG vs KPRX Comparison
GLXG vs KPRX Comparison
Compare GLXG & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLXG
- KPRX
- Stock Information
- Founded
- GLXG 2013
- KPRX 1998
- Country
- GLXG Hong Kong
- KPRX United States
- Employees
- GLXG N/A
- KPRX N/A
- Industry
- GLXG
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GLXG
- KPRX Health Care
- Exchange
- GLXG NYSE
- KPRX Nasdaq
- Market Cap
- GLXG 11.1M
- KPRX 9.1M
- IPO Year
- GLXG 2024
- KPRX N/A
- Fundamental
- Price
- GLXG $0.55
- KPRX $2.90
- Analyst Decision
- GLXG
- KPRX Strong Buy
- Analyst Count
- GLXG 0
- KPRX 1
- Target Price
- GLXG N/A
- KPRX $10.00
- AVG Volume (30 Days)
- GLXG 174.0K
- KPRX 1.3M
- Earning Date
- GLXG 08-16-2025
- KPRX 08-08-2025
- Dividend Yield
- GLXG N/A
- KPRX N/A
- EPS Growth
- GLXG N/A
- KPRX N/A
- EPS
- GLXG N/A
- KPRX N/A
- Revenue
- GLXG $3,711,233.00
- KPRX $20,000.00
- Revenue This Year
- GLXG N/A
- KPRX N/A
- Revenue Next Year
- GLXG N/A
- KPRX N/A
- P/E Ratio
- GLXG N/A
- KPRX N/A
- Revenue Growth
- GLXG N/A
- KPRX N/A
- 52 Week Low
- GLXG $0.39
- KPRX $2.51
- 52 Week High
- GLXG $16.93
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- GLXG N/A
- KPRX 43.33
- Support Level
- GLXG N/A
- KPRX $2.87
- Resistance Level
- GLXG N/A
- KPRX $3.22
- Average True Range (ATR)
- GLXG 0.00
- KPRX 0.18
- MACD
- GLXG 0.00
- KPRX -0.02
- Stochastic Oscillator
- GLXG 0.00
- KPRX 5.77
About GLXG GALAXY PAYROLL GROUP LTD
Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.